Compare ZH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZH | BDTX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.6M | 148.1M |
| IPO Year | 2021 | 2020 |
| Metric | ZH | BDTX |
|---|---|---|
| Price | $3.39 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.60 |
| AVG Volume (30 Days) | 274.0K | ★ 1.6M |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.17 | ★ 0.38 |
| Revenue | ★ $416,437,241.00 | $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.08 | ★ $7.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.19 | $1.20 |
| 52 Week High | $6.32 | $4.94 |
| Indicator | ZH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 34.12 |
| Support Level | $3.29 | $2.52 |
| Resistance Level | $3.58 | $2.69 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 44.93 | 28.77 |
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.